Vericel (VCEL) Stock Price, News & Analysis

Company Overview

Vericel Corporation is a biotechnology company focused on developing and commercializing advanced cell therapies for patients with severe diseases and unmet medical needs. Its core mission is to harness the regenerative potential of autologous cell products to restore tissue function in musculoskeletal and severe burn injuries. The company operates research and manufacturing facilities that support the isolation, expansion and delivery of patient-specific therapeutic cells.

Vericel’s principal commercial products include Epicel®, an autologous cultured epidermal graft approved for the treatment of pediatric and adult patients with deep partial-thickness and full-thickness burns, and MACI® (autologous cultured chondrocytes on porcine collagen membrane), indicated for repairing symptomatic cartilage defects of the knee. These therapies are manufactured from a small biopsy of the patient’s own cells, which are then expanded under controlled conditions and returned for surgical implantation.

Originally formed through a spin-out from Genzyme’s tissue repair business in 2007 under the name Tissue Repair, the company rebranded as Vericel in 2013. It is headquartered in Cambridge, Massachusetts, with a commercial manufacturing site in Hopkinton, Massachusetts. Over the years, Vericel has established quality systems and regulatory expertise to support FDA-approved cell therapy manufacturing and distribution.

Vericel markets its products primarily in the United States, selling directly to hospitals and surgical centers that treat severe burn and cartilage injury patients. Under the leadership of President and Chief Executive Officer Jonathan G. Beck, the company is also advancing its pipeline of next-generation cell therapies and exploring strategic collaborations to broaden its geographic footprint and address new indications. Vericel’s ongoing clinical and manufacturing investments aim to enhance patient access to regenerative treatments in orthopedics and reconstructive medicine.

Key Stats

• Today's Range: $35.00 to $36.06
• 50-Day Range: $35.34 to $45.70
• 52-Week Range: $35.00 to $63.00
• Volume: 122,922 shs
• Average Volume: 478,986 shs
• Market Capitalization: $1.76 billion
• P/E Ratio: 1,168.22
• Dividend Yield: N/A
• Price Target: $61.14
• Consensus Rating: Buy

Vericel Stock Analysis - MarketRank™

Vericel scored higher than 76% of companies evaluated by MarketBeat, and ranked 234th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Vericel has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Vericel has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 214.29%

Earnings Growth

Earnings for Vericel are expected to grow by 214.29% in the coming year, from $0.14 to $0.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vericel is 1,174.56, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vericel is 1,174.56, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.18.

Price to Book Value per Share Ratio

Vericel has a P/B Ratio of 5.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.89% of the float of Vericel has been sold short.

Short Interest Ratio / Days to Cover

Vericel has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vericel has recently decreased by 71.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vericel does not currently pay a dividend.

Dividend Growth

Vericel does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.89% of the float of Vericel has been sold short.

Short Interest Ratio / Days to Cover

Vericel has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vericel has recently decreased by 71.77%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 0.99

News Sentiment

Vericel has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Vericel this week, compared to 6 articles on an average week.

Search Interest

4 people have searched for VCEL on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

1 people have added Vericel to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vericel insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.20% of the stock of Vericel is held by insiders.

VCEL Stock Analysis - Frequently Asked Questions

How have VCEL shares performed this year?

Vericel's stock was trading at $54.91 at the beginning of the year. Since then, VCEL shares have decreased by 35.8% and is now trading at $35.2250.

How were Vericel's earnings last quarter?

Vericel Corporation (NASDAQ:VCEL) posted its quarterly earnings data on Thursday, May, 8th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.14. The company's revenue was up 2.6% compared to the same quarter last year.
Read the conference call transcript.

Who are Vericel's major shareholders?

Vericel's top institutional shareholders include Congress Asset Management Co. (3.46%), Kopp Family Office LLC (0.34%), Truist Financial Corp (0.12%) and State of Alaska Department of Revenue (0.06%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Paul K Wotton, Robert L Md Zerbe, Joseph Anthony Mara Jr, Steven C Gilman, Jonathan Siegal, Michael Halpin and Sean C Flynn.
View institutional ownership trends.

How do I buy shares of Vericel?

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vericel investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Palo Alto Networks (PANW) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/21/2025
• Next Earnings (Estimated): 7/31/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VCEL
• CIK: 887359
• Web: www.vcel.com
• Phone: (617) 588-5555
• Fax: 617-588-5554
• Employees: 300
• Year Founded: 1989

Price Target and Rating

• Average Price Target for Vericel: $61.14
• High Price Target: $67.00
• Low Price Target: $51.00
• Potential Upside/Downside: +73.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.03
• Trailing P/E Ratio: 1,178.39
• Forward P/E Ratio: 252.43
• P/E Growth: N/A
• Net Income: $10.36 million
• Net Margins: 1.25%
• Pretax Margin: 1.31%
• Return on Equity: 1.09%
• Return on Assets: 0.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.01
• Quick Ratio: 4.58

Sales & Book Value

• Annual Sales: $238.54 million
• Price / Sales: 7.46
• Cash Flow: $0.31 per share
• Price / Cash Flow: 113.09
• Book Value: $5.92 per share
• Price / Book: 5.97

Miscellaneous

• Outstanding Shares: 50,343,000
• Free Float: 46,718,000
• Market Cap: $1.78 billion
• Optionable: Optionable
• Beta: 1.32